Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bioworks has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, WAX, ROBERT A. The application is being processed within a distinct art unit, reflecting a focused prosecution environment for this specific matter. Having only the pending office action indicates that the current activity is limited to a single case.
WAX, ROBERT A is the busiest examiner for the company, which constitutes the entirety of the pending workload. With only the action and art unit involved, the prosecution strategy is concentrated on the feedback from a single official. This ratio between actions and examiners simplifies the tracking of deadlines and examiner preferences.
The prosecution environment for this pending office action is highly specific to the Biotechnology & Pharmaceuticals area. With a distinct art unit involved, the legal team can tailor its arguments to the specific precedents and practices of that group. The strategy remains uncomplicated by competing examiner priorities, as WAX, ROBERT A is the only official currently reviewing the company's workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18998335 | Method for Preparing Fiber Deodorant Composition | WAX, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18998335 | Method for Preparing Fiber Deodorant Composition | WAX, ROBERT A | 1615 | §102§103§112 | Non-Final OA | — | Pending | Mar 10, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBioworks has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Wax has the most, with 1 of Bioworks's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
